Compare CAKE & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAKE | MIRM |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 5.4B |
| IPO Year | 1996 | 2019 |
| Metric | CAKE | MIRM |
|---|---|---|
| Price | $59.22 | $92.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $59.47 | ★ $114.67 |
| AVG Volume (30 Days) | ★ 1.4M | 704.8K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 3.06 | N/A |
| Revenue | ★ $3,751,806,000.00 | $19,138,000.00 |
| Revenue This Year | $6.16 | $24.61 |
| Revenue Next Year | $6.60 | $21.75 |
| P/E Ratio | $18.82 | ★ N/A |
| Revenue Growth | ★ 4.75 | N/A |
| 52 Week Low | $43.00 | $36.88 |
| 52 Week High | $69.70 | $109.28 |
| Indicator | CAKE | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 48.00 |
| Support Level | $57.03 | $72.17 |
| Resistance Level | $64.56 | $107.51 |
| Average True Range (ATR) | 2.23 | 4.04 |
| MACD | -0.88 | -0.56 |
| Stochastic Oscillator | 27.10 | 30.40 |
The Cheesecake Factory Inc is a restaurant company that owns and operates multiple casual dining brands across the United States and Canada under brands that include The Cheesecake Factory, North Italia, Flower Child, and additional brands within its Fox Restaurant Concepts portfolio. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, Other FRC, and Other. The majority of the company's revenue comes from the Cheesecake Factory restaurants segment.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.